Search

Your search keyword '"Le, Kang"' showing total 114 results

Search Constraints

Start Over You searched for: Author "Le, Kang" Remove constraint Author: "Le, Kang" Database Unpaywall Remove constraint Database: Unpaywall
114 results on '"Le, Kang"'

Search Results

1. CBP/P300 BRD Inhibition Reduces Neutrophil Accumulation and Activates Antitumor Immunity in TNBC

10. Inhibition of the CEBPβ-NFκB interaction by nanocarrier-packaged Carnosic acid ameliorates glia-mediated neuroinflammation and improves cognitive function in an Alzheimer’s disease model

11. Multi-disciplinary efforts to evaluate the therapeutic potential of CDK11, a novel transcription associated cyclin dependent kinase.

19. Abstract 1102: Integrated approach towards defining mechanism based combinations to guide clinical development of glutaminase inhibitors

20. Abstract 2338: The GLS1 inhibitor IPN60090 enhances antitumor immune response through metabolic reprogramming of T cells and impacts on the tumor microenvironment

21. Abstract 87: Asparagine synthetase (ASNS) expression predicts response to the GLS1 inhibitor IPN60090 in ovarian cancer through selective modulation of redox homeostasis

24. Inhibition of dual leucine zipper kinase prevents chemotherapy-induced peripheral neuropathy and cognitive impairments

28. Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties

31. Dual Leucine Zipper Kinase Is Constitutively Active in the Adult Mouse Brain and Has Both Stress-Induced and Homeostatic Functions

33. First-time disclosure of IPN60090, a potent and selective GLS1 inhibitor with excellent physicochemical properties, targeting cancers with specific metabolic vulnerabilities

34. First-time disclosure of IPN60090, a potent and selective GLS1 inhibitor with excellent physicochemical properties, targeting cancers with specific metabolic vulnerabilities

35. First-time disclosure of IPN60090, a potent and selective GLS1 inhibitor with excellent physicochemical properties, targeting cancers with specific metabolic vulnerabilities

36. First-time disclosure of IPN60090, a potent and selective GLS1 inhibitor with excellent physicochemical properties, targeting cancers with specific metabolic vulnerabilities

37. First-time disclosure of IPN60090, a potent and selective GLS1 inhibitor with excellent physicochemical properties, targeting cancers with specific metabolic vulnerabilities

38. First-time disclosure of IPN60090, a potent and selective GLS1 inhibitor with excellent physicochemical properties, targeting cancers with specific metabolic vulnerabilities

39. First-time disclosure of IPN60090, a potent and selective GLS1 inhibitor with excellent physicochemical properties, targeting cancers with specific metabolic vulnerabilities

40. First-time disclosure of IPN60090, a potent and selective GLS1 inhibitor with excellent physicochemical properties, targeting cancers with specific metabolic vulnerabilities

41. First-time disclosure of IPN60090, a potent and selective GLS1 inhibitor with excellent physicochemical properties, targeting cancers with specific metabolic vulnerabilities

42. First-time disclosure of IPN60090, a potent and selective GLS1 inhibitor with excellent physicochemical properties, targeting cancers with specific metabolic vulnerabilities

Catalog

Books, media, physical & digital resources